|
|
|
In this report
September added a first positive phase 3 signal for individualized neoantigen therapy, alongside a new post-immunotherapy kidney-cancer option. It also sharpened the limits of unselected checkpoint treatment and pushed immune-cell engagers and ADC combinations further into development. The clinical claims are strongest where randomised data or regulatory review exists; several other moves remain early, subgroup-specific, or preclinical.
- Merck and Moderna reported positive recurrence-free and distant metastasis-free survival topline results from the 1,137-patient INTerpath-001 melanoma trial.
- The FDA approved belzutifan plus lenvatinib after prior PD-1/PD-L1 therapy in clear-cell RCC, while atezolizumab failed to reach statistical significance in neoadjuvant TNBC.
- AstraZeneca and GSK committed capital to immune-oncology combinations and a trispecific myeloma engager before either programme has definitive clinical validation.
|
|
Merck and Moderna report positive melanoma vaccine trialCancer vaccines and neoantigens
The 1,137-patient phase 3 INTerpath-001 trial met its recurrence-free survival primary endpoint and distant metastasis-free survival secondary endpoint for individualized mRNA-4157/V940 plus pembrolizumab versus pembrolizumab alone. It is the first positive phase 3 result for an individualized neoantigen therapy, but the announcement does not yet establish the size or durability of benefit.
- The double-blind trial enrolled patients with completely resected stage IIB–IV cutaneous melanoma and randomised them 2:1; full data and regulatory submissions are pending.
- The treatment used tumour and blood sequencing with an algorithm selecting up to 34 candidate neoantigens, alongside pembrolizumab.
What this means for you Individualized neoantigen therapy has crossed an important evidentiary threshold, but effect size, subgroup behaviour, and longer-term durability remain the key unanswered questions for translational immuno-oncology. |
|
FDA approves belzutifan and lenvatinib for ccRCCImmune checkpoint inhibitors
The FDA approved belzutifan plus lenvatinib for advanced clear-cell RCC after prior PD-1/PD-L1 therapy. In LITESPARK-011, the combination improved median progression-free survival over cabozantinib, although final overall survival did not reach statistical significance.
- Median PFS was 14.6 versus 10.6 months, with a hazard ratio of 0.74; objective response was 53% versus 40%.
- The label includes warnings for embryo-fetal harm, severe anaemia, hypoxia, and cardiac dysfunction including reduced LVEF with lenvatinib.
What this means for you Post-checkpoint ccRCC now has an approved HIF-2α/VEGFR-TKI combination with a PFS advantage, while overall-survival interpretation and tolerability remain part of the treatment landscape. |
|
AstraZeneca funds Summit’s ivonescimab ADC combinationsImmuno-oncology industry landscape
AstraZeneca invested $2 billion in Summit Therapeutics and agreed to evaluate ivonescimab with the CLDN18.2-targeting ADC Sone-Ve in gastrointestinal cancers. The agreement also leaves room for combinations with AstraZeneca’s wider ADC portfolio, making this a capital and development commitment rather than clinical proof.
- Ivonescimab is a PD-1/VEGF bispecific licensed from Akeso, with trials running across several tumour types and a US BLA under review in EGFR-mutated NSCLC.
- Sone-Ve has reported overall-survival results in CLDN18.2-positive advanced gastric cancer; the companies will jointly contribute to combination trials while retaining rights to their own medicines.
What this means for you The commercial thesis is moving toward pairing immune modulation with differentiated ADC payloads, but the value of the combination still depends on prospective efficacy, sequencing, and toxicity data. |
|
GSK acquires Chimagen’s trispecific myeloma engagerImmuno-oncology industry landscape
GSK agreed to acquire Chimagen’s multiple-myeloma trispecific T-cell engager for up to $750 million in upfront and milestone payments. The programme is expected to enter phase 1 in 2027, so the transaction reflects a development thesis about deeper targeting and tolerability, not demonstrated patient benefit.
- The asset is designed to bind T cells while targeting two tumour-associated antigens, a proposed way to improve response depth and reduce the limitations of current T-cell engagers.
- GSK already has a relationship with Chimagen through a separate CD19/CD20-targeted engager programme.
What this means for you Myeloma development is placing more weight on differentiated engager architecture and tolerability, but the clinical value of this design will not be testable until early human data arrive. |
|
Atezolizumab misses the primary endpoint in TNBCImmune checkpoint inhibitors
In the 1,550-patient phase 3 NSABP B-59/GeparDouze trial, adding atezolizumab to neoadjuvant chemotherapy did not produce statistically significant event-free or overall-survival benefit in stage II–III TNBC. The result contrasts with pembrolizumab in KEYNOTE-522 and argues against treating checkpoint benefit as interchangeable across regimens.
- EFS was not significant, with a hazard ratio of 0.80 and p=0.083; the four-year difference was 3.3%, while the four-year OS difference was 0.7%.
- Exploratory signals appeared in node-positive and basal-like immune-activated subgroups, but grade 3 or higher adverse events occurred in 75.3% versus 73.4% and 25.5% discontinued atezolizumab during neoadjuvant treatment.
What this means for you In neoadjuvant TNBC, agent, population, chemotherapy backbone, and biomarker context remain clinically consequential; a positive checkpoint precedent does not transfer automatically. |
|
Study links lactylation to checkpoint resistance in ESCCImmunotherapy biomarkers and resistance
A September study in esophageal squamous cell carcinoma identified a mechanistic route from tumour lactate to immune checkpoint resistance. In models, KAT5-mediated lactylation of HSPA1A stabilised STAT1, increased PD-L1, impaired CD8-positive T-cell function, and reduced anti-PD-1 activity.
- The proposed chain is HSPA1A lysine-108 lactylation, protection from TRIM25-mediated degradation, STAT1 activation, and PD-L1 transcription.
- Lactylation blockade restored anti-PD-1 activity in ESCC models, while elevated global lactylation correlated with resistance and poorer prognosis in patient material.
What this means for you Resistance biology is becoming more testable at the interface of metabolism, post-translational modification, and antigen-presentation signalling, although this mechanism is not yet a validated clinical biomarker or treatment strategy. |
|
FDA clears first MAIT-cell engager for phase 1Bispecific antibodies in oncology
FDA review cleared Biomunex and Ipsen’s IPN60330 to begin a US phase 1 trial, introducing a GPC3-directed bispecific designed to engage mucosal-associated invariant T cells. The milestone expands the cell-engager design space, but it is an IND clearance rather than evidence of clinical activity or a wider therapeutic window.
- IPN60330 is intended to activate a specialised T-cell subset enriched in mucosal and barrier tissues while targeting GPC3 across several tumour types.
- The proposed rationale is more selective immune activation than classical pan-T-cell engagers, whose cytokine-release and tolerability profiles can limit treatment.
What this means for you MAIT-cell engagement has moved from platform proposition to first-in-human testing, with pharmacology, cytokine release, persistence, and tumour targeting now the relevant evidence. |
|
EMB-01 shows narrow activity in pretreated colorectal cancerBispecific antibodies in oncology
The EGFR/c-MET bispecific EMB-01 produced its clearest activity in a defined left-sided, RAS/RAF-wild-type, treatment-naive subgroup of heavily pretreated metastatic colorectal cancer. The signal is clinically bounded by a 63.5% rate of grade 3 or higher treatment-related adverse events.
- Confirmed response was 12.5% across 48 mCRC patients, rising to 20.7% in the prespecified favourable subgroup, with median progression-free survival of 19 weeks.
- All patients experienced at least one treatment-related adverse event; rash and acneiform dermatitis were prominent, consistent with EGFR blockade.
What this means for you Dual-target bispecific activity remains dependent on molecular and anatomical selection, while toxicity continues to define how much of the observed response is clinically usable. |
|
TCR-like CAR-NK cells target MAGE-A4 in modelsCell therapies (CAR-T and beyond)
A preclinical study engineered CAR-NK cells to recognise the MAGE-A4 peptide presented by HLA-A*02:01, addressing the shortage of suitable surface antigens in solid tumours. The cells showed antigen-specific killing and controlled melanoma xenografts, but the evidence remains confined to models.
- MAGE-A4 CAR-NK-92 cells killed MAGE-A4-positive melanoma, osteosarcoma, and myeloma lines but not a MAGE-A4-negative colorectal line.
- The same construct increased degranulation, granzyme B, perforin, TNF-α, and IFN-γ, with activity reproduced in primary NK cells.
What this means for you Peptide-HLA recognition is extending the potential antigen space for solid-tumour CAR-NK work, while HLA restriction, antigen heterogeneity, persistence, and clinical translation remain unresolved. |
|
How Iris covered your topics this month Every topic you track was searched over the last month. | Topic | Sources found | In this briefing | | Immune checkpoint inhibitors | 16 | 2 stories | | Cell therapies (CAR-T and beyond) | 12 | 1 story | | Cancer vaccines and neoantigens | 9 | 1 story | | Bispecific antibodies in oncology | 14 | 2 stories | | Immunotherapy biomarkers and resistance | 13 | 1 story | | Immuno-oncology industry landscape | 11 | 2 stories |
|
|
